Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.

Date publication

mai 2023

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard

Tous les auteurs :
Royer B, Launay M, Ciccolini J, Derain L, Parant F, Thomas F, Guitton J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37267808

Résumé

The chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping.

Mots clés

DPD phenotype, dihydropyrimidine dehydrogenase—DPD, fluoropyrimidine, multicentric study, renal impairment, uracil

Référence

ESMO Open. 2023 05 31;8(3):101577